Lilly Drugs - Search News

Eli Lilly Q4 2024 Earnings Preview

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before

Hosted on MSN · 2d

What Analysts Think of Eli Lilly Stock Ahead of Earnings

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday.Analysts tracking the company see increased sales and profit for Eli Lilly in the first full period in which its weight-loss drugs ceased to be in shortage.

Seeking Alpha · 15h

Eli Lilly Q4 2024 Earnings Preview: All eyes on stronger 2025

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

AOL · 13d

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion. Recently,

Investing.com on MSN · 12h

Erste Group raises Eli Lilly stock rating to Buy, sees strong sales

Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's significant sales growth expected this year along with a positive earnings outlook.

Novo Nordisk's next-gen obesity drug Cagrisema

AOL · 1d

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

CNBC on MSN · 12h

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Reuters on MSN · 1d

Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.

22h

Lilly needs a plan to spur weight-loss drug sales, investors say

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

11hon MSN

Eli Lilly’s Results Already Disappointed the Street. More Details Come Thursday.

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

STAT18h

Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

10d

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

13h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results